Digital Patient Access Solutions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ Lupin Pharmaceuticals Inc. (Lupin), global pharmaceutical company, announced today a partnership with Phil, Inc., which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.
Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet.
1 In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021. ....

United States , San Francisco , Deepak Thomas , Manjira Sharma , Jon Stelzmiller , Shweta Munjal , Arvind Bothra , Digital Patient Access Solutions , Lupin Pharmaceuticals Inc , Drug Administration , Lupin Inc , Phil Inc , Physician Research , American College Of Obstetricians , Corporate Communications , Prnewswire Lupin Pharmaceuticals Inc , Advantage Healthcare Inc , New Drug Application , Prescription Drug User Fee Act , Lupin Pharmaceuticals , Lupin Limited , Harbor Statement , Private Securities Litigation Reform Act , Investor Relations , Digital Patient Access , Clinical Management Guidelines ,